BIOGEN INC. — Director's Dealing 2020

Mar 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2020-03-11

Reporting Person: SHERWIN STEPHEN A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-11	Common Stock	M	10923	$58.46	Acquired	16517	Direct
2020-03-11	Common Stock	S	2164	$295.215	Disposed	14353	Direct
2020-03-11	Common Stock	M	1355	$58.46	Acquired	15708	Direct
2020-03-11	Common Stock	S	270	$295.29	Disposed	15438	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-11	Stock Option (Right to Buy)	$59.82	M	10923	Disposed	2020-03-22	Common Stock (10923)	Direct
2020-03-11	Stock Option (Right to Buy)	$59.82	M	1355	Disposed	2020-03-22	Common Stock (1355)	Direct

Footnotes

F1: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.

F3: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.

F4: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).

F5: The stock options become exercisable in three (3) equal annual installments commencing one year after the grant date of 03/22/2010.